Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT02983734
PHASE2

D-cycloserine: A Novel Treatment for Gulf War Illness (GWDCS)

Sponsor: Boston University Charles River Campus

View on ClinicalTrials.gov

Summary

The purpose of this study is to investigate the efficacy of d-cycloserine (DCS) treatment for Gulf War Illness (GWI). Gulf War veterans with Gulf War Illness experience numerous chronic health symptoms, including cognition and fatigue, which reduces their quality of life. Gulf War veterans are in urgent need of novel treatment plans to tackle elusive symptomatology of Gulf War Illness. By using the literature of previous studies, the investigators have chosen to investigate d-cycloserine as a possible candidate for treating GWI, specifically cognitive symptoms. DCS has been shown to reduce neuroinflammation, regulate glutamate levels, and improve synaptic functioning in key areas of the brain.

Official title: D-cycloserine: A Novel Treatment for Gulf War Illness

Key Details

Gender

All

Age Range

43 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

22

Start Date

2015-10

Completion Date

2019-09-15

Last Updated

2026-09-09

Healthy Volunteers

No

Interventions

DRUG

D-cycloserine

100mg of DCS will be administered orally in pill form daily for 4 weeks

DRUG

Placebo

A placebo will be administered orally daily for 4 weeks

Locations (1)

Boston University

Boston, Massachusetts, United States